Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck’s Global Human Health President Schechter Leaving at End of Year

By Mike Botta | December 11, 2018

Merck, known as MSD outside the United States and Canada, announced that Adam H. Schechter, president of Global Human Health, is stepping down from his current position as of December 31, and shifting to an advisory capacity.

The move is part of a company plan to reshape its commercial organization, which will create two new executive committee roles, according to Merck. Frank Clyburn has been promoted to chief commercial officer and Michael Nally has been promoted to chief marketing officer, both effective January 1.

Schechter, who joined the company 30 years ago, has been the president of Global Human Health since 2010. In addition to his work in Merck’s commercial organization, he led the integration of Merck and Schering-Plough Corp. followiing the $41 billion merger in 2009.

Clyburn, who joined Merck in 2008, has held a number of leadership positions across the company. Most recently, he served as president of the Global Oncology business. In his new role, Clyburn will report directly to Ken Frazier, chairman and CEO, and will be a member of the executive committee. He will be responsible for all operations and P&L across Merck’s human health commercial portfolio globally. Over the years he has had responsibility for several global pharmaceutical franchises, including diabetes, cardiovascular, and women’s health, as well as leadership of marketing and sales teams.

Nally, who has been at Merck since 2003, most recently led the company’s Vaccines business. He, too, will report directly to Frazier and will be a member of the executive committee. Nally will be responsible for global marketing and long-term franchise strategy across the portfolio. He has served in a number of roles, including managing director of U.K., Ireland, and Sweden, and in commercial operations, business development, and investor relations.

(Source: Merck & Co., Inc.)

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE